A novel anti-infective molecule nesfactin identified from sponge associated bacteria Nesterenkonia sp. MSA31 against multidrug resistant Pseudomonas aeruginosa

Kiran, George Seghal; Sajayan, Arya; Priyadharshini, Gopal Balasubramian; Balakrishnan, Aarthy; Prathiviraj, R.; Sabu, Abdulhameed; Selvin, Joseph

doi:10.1016/j.micpath.2021.104923

Cited by 13 publications

(7 citation statements)

References 53 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Actinosporins A and C (146,144) were isolated from the axenic cultures of strain EG49. Actinosporin A showed anti-trypanosomal activity and actinosporin C exhibited antioxidant activity.…”

Section: Polyketidesmentioning

confidence: 99%

“…A novel anti-infective molecule nesfactin (255) (Figure 12) was isolated from spongeassociated Nesterenkonia sp. MSA31 and active against multidrug-resistant Pseudomonas aeruginosa by inhibiting the phenotypic expression of virulence factors [144]. Three antifungal cycle peptides Rhodopeptins C1, C2, and B5 (256-258) (Figure 12) were obtained from Rhodococcus sp.…”

Section: Peptidesmentioning

confidence: 99%

See 1 more Smart Citation

Natural Products from Actinomycetes Associated with Marine Organisms

Chen

Zhou

et al. 2021

Marine Drugs

View full text Add to dashboard Cite

The actinomycetes have proven to be a rich source of bioactive secondary metabolites and play a critical role in the development of pharmaceutical researches. With interactions of host organisms and having special ecological status, the actinomycetes associated with marine animals, marine plants, macroalgae, cyanobacteria, and lichens have more potential to produce active metabolites acting as chemical defenses to protect the host from predators as well as microbial infection. This review focuses on 536 secondary metabolites (SMs) from actinomycetes associated with these marine organisms covering the literature to mid-2021, which will highlight the taxonomic diversity of actinomycetes and the structural classes, biological activities of SMs. Among all the actinomycetes listed, members of Streptomyces (68%), Micromonospora (6%), and Nocardiopsis (3%) are dominant producers of secondary metabolites. Additionally, alkaloids (37%), polyketides (33%), and peptides (15%) comprise the largest proportion of natural products with mostly antimicrobial activity and cytotoxicity. Furthermore, the data analysis and clinical information of SMs have been summarized in this article, suggesting that some of these actinomycetes with multiple host organisms deserve more attention to their special ecological status and genetic factors.

show abstract

“…Actinosporins A and C (146,144) were isolated from the axenic cultures of strain EG49. Actinosporin A showed anti-trypanosomal activity and actinosporin C exhibited antioxidant activity.…”

Section: Polyketidesmentioning

confidence: 99%

Section: Peptidesmentioning

confidence: 99%

Natural Products from Actinomycetes Associated with Marine Organisms

Chen

Zhou

et al. 2021

Marine Drugs

View full text Add to dashboard Cite

show abstract

“…Molecular docking studies showed that the LasR protein had binding energy—4.5 kcal/mol. It has two hydrogen-bonding interactions (Ala59 and Lys34 with binding distance of 2.8 and 3.5 Ằ) and one hydrophobic interaction (Ala58:4.01381) against 54 [ 38 ].…”

Section: Secondary Metabolites From Marine-derived Bacteria Which Wer...mentioning

confidence: 99%

Secondary Metabolites from Marine-Derived Bacteria with Antibiotic and Antibiofilm Activities against Drug-Resistant Pathogens

Wibowo¹,

Bayu²,

Aryati

et al. 2023

Marine Drugs

View full text Add to dashboard Cite

The search for new antibiotics against drug-resistant microbes has been expanded to marine bacteria. Marine bacteria have been proven to be a prolific source of a myriad of novel compounds with potential biological activities. Therefore, this review highlights novel and bioactive compounds from marine bacteria reported during the period of January 2016 to December 2021. Published articles containing novel marine bacterial secondary metabolites that are active against drug-resistant pathogens were collected. Previously described compounds (prior to January 2016) are not included in this review. Unreported compounds during this period that exhibited activity against pathogenic microbes were discussed and compared in order to find the cue of the structure–bioactivity relationship. The results showed that Streptomyces are the most studied bacteria with undescribed bioactive compounds, followed by other genera in the Actinobacteria. We have categorized the structures of the compounds in the present review into four groups, based on their biosynthetic origins, as polyketide derivatives, amino acid derivatives, terpenoids, as well as compounds with mixed origin. These compounds were active against one or more drug-resistant pathogens, such as methicillin-resistant Staphylococcus aureus (MRSA), methicillin-resistant Staphylococcus epidermidis (MRSE), vancomycin-resistant Enterococci (VRE), multidrug-resistant Mycobacterium tuberculosis (MDR-TB), and amphotericin B-resistant Candida albicans. In addition, some of the compounds also showed activity against biofilm formation of the test bacteria. Some previously undescribed compounds, isolated from marine-derived bacteria during this period, could have a good potential as lead compounds for the development of drug candidates to overcome multidrug-resistant pathogens.

show abstract

“…The Nesfactin lipopeptide, produced by marine bacteria Nesterenkonia sp. MSA31, was recently isolated and characterized by Kiran and collaborators [ 166 ]. The protease, esterase, lipase, and phospholipase activities, representing virulence phenotypes, were significantly reduced in both P. aeruginosa PAO1 and FSPA02 when treated with 50 µg/mL of Nesfactin.…”

Section: Marine Natural Products Against P Aeruginosamentioning

confidence: 99%

“…In addition, the production of the virulence factors pyocyanin, alginate, elastase, and rhamnolipid in PAO1 and FSPA02 was also reduced by 70%, 65%, 79%, and 75%, respectively, in the presence of 50 µg/mL of the lipopeptide. Finally, Nesfactin at 100 µg/mL disrupted 85–90% of the biofilm of both P. aeruginosa strains [ 166 ].…”

Section: Marine Natural Products Against P Aeruginosamentioning

confidence: 99%

Exploring Oceans for Curative Compounds: Potential New Antimicrobial and Anti-Virulence Molecules against Pseudomonas aeruginosa

et al. 2022

View full text Add to dashboard Cite

Although several antibiotics are already widely used against a large number of pathogens, the discovery of new antimicrobial compounds with new mechanisms of action is critical today in order to overcome the spreading of antimicrobial resistance among pathogen bacteria. In this regard, marine organisms represent a potential source of a wide diversity of unique secondary metabolites produced as an adaptation strategy to survive in competitive and hostile environments. Among the multidrug-resistant Gram-negative bacteria, Pseudomonas aeruginosa is undoubtedly one of the most important species due to its high intrinsic resistance to different classes of antibiotics on the market and its ability to cause serious therapeutic problems. In the present review, we first discuss the general mechanisms involved in the antibiotic resistance of P. aeruginosa. Subsequently, we list the marine molecules identified up until now showing activity against P. aeruginosa, dividing them according to whether they act as antimicrobial or anti-virulence compounds.

show abstract

A novel anti-infective molecule nesfactin identified from sponge associated bacteria Nesterenkonia sp. MSA31 against multidrug resistant Pseudomonas aeruginosa

Cited by 13 publications

References 53 publications

Natural Products from Actinomycetes Associated with Marine Organisms

Natural Products from Actinomycetes Associated with Marine Organisms

Secondary Metabolites from Marine-Derived Bacteria with Antibiotic and Antibiofilm Activities against Drug-Resistant Pathogens

Exploring Oceans for Curative Compounds: Potential New Antimicrobial and Anti-Virulence Molecules against Pseudomonas aeruginosa

Contact Info

Product

Resources

About